Aytu Bioscience Stock Performance
| AYTU Stock | USD 1.63 0.12 7.95% |
The firm shows a Beta (market volatility) of 0.51, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aytu BioScience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Aytu BioScience is expected to be smaller as well. At this point, Aytu BioScience has a negative expected return of -0.48%. Please make sure to confirm Aytu BioScience's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Aytu BioScience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aytu BioScience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:20 | Dividend Date 2020-12-09 | Last Split Date 2023-01-06 |
1 | Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results | 09/26/2024 |
2 | Disposition of 209 shares by Greg Pyszczymuka of Aytu BioScience subject to Rule 16b-3 | 09/30/2024 |
3 | Acquisition by Greg Pyszczymuka of 7000 shares of Aytu BioScience at 1.84 subject to Rule 16b-3 | 11/06/2024 |
4 | Insider Trading | 11/11/2024 |
5 | Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results | 11/13/2024 |
6 | Earnings call Aytu BioPharma reports first positive net income | 11/14/2024 |
7 | Short Interest in Aytu BioPharma, Inc. Decreases By 14.4 | 11/18/2024 |
8 | Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500 | 11/22/2024 |
| Begin Period Cash Flow | 23 M |
Aytu |
Aytu BioScience Relative Risk vs. Return Landscape
If you would invest 237.00 in Aytu BioScience on August 26, 2024 and sell it today you would lose (74.00) from holding Aytu BioScience or give up 31.22% of portfolio value over 90 days. Aytu BioScience is currently does not generate positive expected returns and assumes 4.3564% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Aytu, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aytu BioScience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aytu BioScience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aytu BioScience, and traders can use it to determine the average amount a Aytu BioScience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.11
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AYTU |
Estimated Market Risk
| 4.36 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aytu BioScience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aytu BioScience by adding Aytu BioScience to a well-diversified portfolio.
Aytu BioScience Fundamentals Growth
Aytu Stock prices reflect investors' perceptions of the future prospects and financial health of Aytu BioScience, and Aytu BioScience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aytu Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0106 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 6.47 M | ||||
| Shares Outstanding | 6.15 M | ||||
| Price To Earning | (0.77) X | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 0.12 X | ||||
| Revenue | 81 M | ||||
| Gross Profit | 66.63 M | ||||
| EBITDA | (1.01 M) | ||||
| Net Income | (15.84 M) | ||||
| Cash And Equivalents | 23.81 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 15.13 M | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.02 X | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | (1.39 M) | ||||
| Earnings Per Share | (1.70) X | ||||
| Market Capitalization | 10.02 M | ||||
| Total Asset | 118.09 M | ||||
| Retained Earnings | (319.97 M) | ||||
| Working Capital | (337 K) | ||||
| Current Asset | 6.36 M | ||||
| Current Liabilities | 8.73 M | ||||
About Aytu BioScience Performance
Assessing Aytu BioScience's fundamental ratios provides investors with valuable insights into Aytu BioScience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aytu BioScience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 174.56 | 241.62 | |
| Return On Tangible Assets | (0.24) | (1.46) | |
| Return On Capital Employed | (0.09) | (1.07) | |
| Return On Assets | (0.13) | (0.46) | |
| Return On Equity | (0.57) | (1.04) |
Things to note about Aytu BioScience performance evaluation
Checking the ongoing alerts about Aytu BioScience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aytu BioScience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aytu BioScience generated a negative expected return over the last 90 days | |
| Aytu BioScience may become a speculative penny stock | |
| Aytu BioScience has high historical volatility and very poor performance | |
| Aytu BioScience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 81 M. Net Loss for the year was (15.84 M) with profit before overhead, payroll, taxes, and interest of 66.63 M. | |
| Aytu BioScience currently holds about 23.81 M in cash with (1.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Aytu BioScience has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500 |
- Analyzing Aytu BioScience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aytu BioScience's stock is overvalued or undervalued compared to its peers.
- Examining Aytu BioScience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aytu BioScience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aytu BioScience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aytu BioScience's stock. These opinions can provide insight into Aytu BioScience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.